Publication date: Feb 12, 2025
Whereas several studies have demonstrated the long-term immunogenicity of BNT162b2 vaccine in healthy adults, little evidence was provided in vulnerable populations (VPs) with generally low ability to respond to immunizations. We aimed to identify pre-vaccination immune phenotype and transcriptional signatures in B and T-cell subsets associated with immune response and long-term maintenance upon SARS-CoV-2 vaccination in VPs. A cohort of VPs (N = 169) including solid organ transplant recipients (SOT; N = 35), Inflammatory Bowel Disease (N = 31), Down Syndrome (N = 42), people living with HIV (N = 36), primary immune deficiencies (N = 25) and healthy controls (N = 37) were enrolled in the CONVERS Study. SARS-CoV-2 Vaccine responsiveness was evaluated by SARS-CoV-2-specific Ab and SARS-CoV-2-specific CD4+ T cells in VPs naive to infection or vaccination. Based on the humoral response at T28, individuals were classified as Protected (P: anti-spike antibody [anti-S] titer ≥0. 8) and Not-Protected (NP: anti-S titer
Open Access PDF
| Concepts | Keywords |
|---|---|
| Bnt162b2 | Bnt162b2 |
| Naive | Convers |
| Organ | Cov |
| Pediatric | Healthy |
| Vaccination | Immune |
| Long | |
| Pre | |
| Protected | |
| Sars | |
| Specific | |
| Term | |
| Vaccination | |
| Vaccine | |
| Vps | |
| Vulnerable |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | IDO | cell |
| disease | IDO | immune response |
| disease | MESH | Inflammatory Bowel Disease |
| pathway | KEGG | Inflammatory bowel disease |
| disease | MESH | Down Syndrome |
| disease | MESH | primary immune deficiencies |
| disease | MESH | infection |